- Home
- NXST vs MIRM Comparison
NXST vs MIRM Comparison
Compare NXST & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXST | MIRM |
|---|---|---|
| Founded | 1996 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 5.7B |
| IPO Year | 2002 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NXST | MIRM |
|---|---|---|
| Price | $193.25 | $97.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | ★ $267.75 | $115.33 |
| AVG Volume (30 Days) | 397.7K | ★ 816.6K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.94% | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ 3.00 | N/A |
| Revenue | ★ $4,949,000,000.00 | $19,138,000.00 |
| Revenue This Year | $11.38 | $26.22 |
| Revenue Next Year | N/A | $21.77 |
| P/E Ratio | $62.97 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $141.66 | $37.33 |
| 52 Week High | $254.30 | $109.28 |
Technical Indicators
Market Signals| Indicator | NXST | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 35.58 | 58.30 |
| Support Level | $182.70 | $85.35 |
| Resistance Level | $203.89 | $107.51 |
| Average True Range (ATR) | 10.57 | 3.72 |
| MACD | -3.13 | 1.05 |
| Stochastic Oscillator | 28.32 | 84.05 |
Price Performance
Historical ComparisonAbout NXST Nexstar Media Group Inc.
Nexstar is the largest television station owner-operator in the United States with over 200 stations in 116 markets, reaching 220 million people. Of its 200 stations, 155 are affiliated with the four national broadcast networks: CBS, Fox, NBC, and ABC. Pending approval, Nexstar's merger with Tegna would bring Nexstar's station total to 259 in 133 markets, reaching 80% of the US population. Nexstar also owns NewsNation (formerly WGN), a cable news network, 75% of the fifth national broadcaster, the CW, and a 31% stake in Food Network and Cooking Channel.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.